{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:45:07Z","timestamp":1785908707429,"version":"3.56.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer and heart failure (HF) are highly prevalent in the population and can co-exist, due to shared risk factors and an aging population. The HF-related mortality burden in cancer patients across in the United States (US) remains poorly understood. The goal of this study is to evaluate the patterns of HF-related deaths among cancer patients in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was performed using the Centers for Disease Control and Prevention (CDC) WONDER Multiple Cause of Death database between years 1999 and 2020. HF-related deaths were defined as death certificates listing HF as a contributing cause of death, while HF-specific deaths were defined as those with HF listed as the underlying cause of death. The ten most common malignancies in the US were analyzed. Mortality rates, temporal trends, regional differences, sex- and race-based disparities were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 402,308 HF-related deaths were identified among patients with the ten most common cancers. Lung cancer was associated with the highest rates, accounting for 115,283 deaths (1.71 per 100,000 population), followed by prostate cancer (1.08 per 100,000), colorectal cancer (0.90 per 100,000) and breast cancer (0.84 per 100,000). Most malignancies had increasing HF-related mortality during the latter years of the study period. The Midwest had the highest HF-related mortality rates for several types of cancer. White patients had the highest HF-related mortality rates across all cancer types. Among HF-specific deaths, prostate cancer exhibited the highest mortality rate (594.03 per 100,000).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is a substantial HF-related mortality burden across cancer patients, which is on the rise in recent years. Certain high-risk populations may be identified and cardio-oncology surveillance and targeted cardiovascular risk reduction strategies may be implemented among cancer survivors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1896502","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:50:18Z","timestamp":1785905418000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An analysis of heart failure among cancer patients in the United States between 1999 and 2020"],"prefix":"10.3389","volume":"16","author":[{"given":"Abes A.","family":"Bautista Neughebauer","sequence":"first","affiliation":[{"name":"Department of Cardiology, Eastern Virginia Medical School","place":["Norfolk, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Talreja","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Eastern Virginia Medical School","place":["Norfolk, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Gaitanidis","sequence":"additional","affiliation":[{"name":"Department of Surgery, Eastern Virginia Medical School","place":["Norfolk, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CARDFAIL.2024.08.045","article-title":"Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America","volume":"31","author":"Bloom","year":"2025","journal-title":"J Card Fail"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/CVR\/CVAE038","article-title":"Heart failure-induced microbial dysbiosis contributes to colonic tumour formation in mice","volume":"120","author":"De Wit","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaccao.2022.01.095","article-title":"Association of cardiometabolic disease with cancer in the community","volume":"4","author":"Liu","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B5","article-title":"Steps required to calculate proportionate mortality ratios","year":"2021"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHZ835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/JAMA.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/EURJPC\/ZWAE256","article-title":"Sex differences in long-term heart failure prognosis: a comprehensive meta-analysis","volume":"31","author":"Qiu","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001391","article-title":"Coronary atherosclerosis in patients with cancer and survivors: a scientific statement from the American Heart Association","volume":"153","author":"Zhang","year":"2026","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31561-0","article-title":"Sex and gender: modifiers of health, disease, and medicine","volume":"396","author":"Mauvais-Jarvis","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/J.CARPATH.2025.107735","article-title":"Temporal and demographic disparities in mortality trends for heart failure and COPD-associated heart failure in U.S. adults: a 1999-2020 analysis of CDC WONDER data","volume":"77","author":"Ahmed","year":"2025","journal-title":"Cardiovasc Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/03000605261417063","article-title":"Demographics and mortality trends of hypertensive heart failure in the United States, 2006-2020: insights from the CDC WONDER database","volume":"54","author":"Faizan","year":"2026","journal-title":"J Int Med Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/J.CARDFAIL.2025.07.007","article-title":"HF STATS 2025: heart failure epidemiology and outcomes statistics an updated 2025 report from the Heart Failure Society of America","volume":"32","author":"Fonarow","year":"2026","journal-title":"J Card Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.CARDFAIL.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaccao.2022.10.013","article-title":"Racial and ethnic disparities in all-cause and cardiovascular mortality among cancer patients in the U.S","volume":"5","author":"Zhu","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/CAAC.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2022.03.377","article-title":"Cigarette smoking, cessation, and risk of heart failure with preserved and reduced ejection fraction","volume":"79","author":"Ding","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.05.003","article-title":"Lung cancer and cardiovascular disease: common pathophysiology and treatment-emergent toxicity","volume":"7","author":"El-Rayes","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS17213443","article-title":"A new era, new risks: the cardio-oncology perspective on immunotherapy in non-small cell lung cancer","volume":"17","author":"Tarantini","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.950971","article-title":"Cardiovascular disease and risk of lung cancer incidence and mortality: a nationwide matched cohort study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/S41569-024-01017-X","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/S11912-023-01387-4","article-title":"Cardiovascular toxicity and risk mitigation with lung cancer treatment","volume":"25","author":"Yegya-Raman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00651-5","article-title":"Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review","volume":"27","author":"Kim","year":"2026","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/QJMED\/HCAG089","article-title":"Treatment-related cardiotoxicity in non-small cell lung cancer: a population-based analysis for risk stratification","author":"Mo","year":"2026","journal-title":"QJM"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2025.1601808","article-title":"Cardiovascular adverse effects of immunotherapy in cancer: insights and implications","volume":"15","author":"Du","year":"2025","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:50:20Z","timestamp":1785905420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1896502"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1896502","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1896502"}}